JOSHUA GOLDEN: Open Payments
NPI 1336200849 · ATTLEBORO, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,728 in 40 payments from 7 companies in 2025. Trend: 2023 $788 · 2024 $737 · 2025 $1,728
Food & beverage: $1,728
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $349 |
| Neurocrine BioSciences, Inc. | 4 | $323 |
| Axsome Therapeutics, Inc. | 7 | $277 |
| Vanda Pharmaceuticals Inc. | 5 | $270 |
| E.R. Squibb & Sons, L.L.C. | 3 | $256 |
| Otsuka America Pharmaceutical, Inc. | 2 | $211 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
Products named: VRAYLAR, INGREZZA, Auvelity, FANAPT, COBENFY, REXULTI, CAPLYTA.
Industry payments across MA — which companies pay providers there.
